AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
mechlorethamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1647 | 51-75-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 | 38 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,CDK4,EPHB4,GAK,MAPK10,MAPK7,PDK4,PRKCD,SIK2,STK33,TEK | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 15, 1949 | FDA | RECORDATI RARE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 484.37 | 51.68 | 83 | 1864 | 4164 | 90622336 |
| Application site pain | 382.41 | 51.68 | 69 | 1878 | 4651 | 90621849 |
| Application site erythema | 349.91 | 51.68 | 65 | 1882 | 5143 | 90621357 |
| Application site discolouration | 248.99 | 51.68 | 38 | 1909 | 900 | 90625600 |
| Application site irritation | 227.83 | 51.68 | 39 | 1908 | 1922 | 90624578 |
| Skin discolouration | 173.91 | 51.68 | 56 | 1891 | 44259 | 90582241 |
| Pruritus | 155.92 | 51.68 | 112 | 1835 | 541413 | 90085087 |
| Skin irritation | 147.64 | 51.68 | 38 | 1909 | 13565 | 90612935 |
| Application site vesicles | 128.03 | 51.68 | 23 | 1924 | 1494 | 90625006 |
| Erythema | 121.82 | 51.68 | 70 | 1877 | 229176 | 90397324 |
| Application site dryness | 109.26 | 51.68 | 15 | 1932 | 162 | 90626338 |
| Skin burning sensation | 85.93 | 51.68 | 27 | 1920 | 19584 | 90606916 |
| Application site discharge | 84.93 | 51.68 | 12 | 1935 | 162 | 90626338 |
| Therapy non-responder | 83.98 | 51.68 | 46 | 1901 | 136658 | 90489842 |
| Application site exfoliation | 81.09 | 51.68 | 13 | 1934 | 424 | 90626076 |
| Application site inflammation | 75.44 | 51.68 | 12 | 1935 | 372 | 90626128 |
| Cutaneous T-cell lymphoma | 70.05 | 51.68 | 14 | 1933 | 1606 | 90624894 |
| Skin hyperpigmentation | 63.96 | 51.68 | 17 | 1930 | 6834 | 90619666 |
| Application site swelling | 55.82 | 51.68 | 10 | 1937 | 637 | 90625863 |
| Application site rash | 52.22 | 51.68 | 12 | 1935 | 2657 | 90623843 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 503.83 | 58.09 | 84 | 2033 | 1494 | 42617724 |
| Application site erythema | 450.00 | 58.09 | 82 | 2035 | 2484 | 42616734 |
| Application site pain | 360.41 | 58.09 | 67 | 2050 | 2262 | 42616956 |
| Application site irritation | 191.69 | 58.09 | 33 | 2084 | 707 | 42618511 |
| Pruritus | 190.48 | 58.09 | 117 | 2000 | 188654 | 42430564 |
| Skin irritation | 180.80 | 58.09 | 47 | 2070 | 7527 | 42611691 |
| Application site vesicles | 173.84 | 58.09 | 30 | 2087 | 652 | 42618566 |
| Therapy non-responder | 130.62 | 58.09 | 60 | 2057 | 53299 | 42565919 |
| Application site discolouration | 120.67 | 58.09 | 20 | 2097 | 337 | 42618881 |
| Erythema | 118.30 | 58.09 | 71 | 2046 | 108722 | 42510496 |
| Application site discharge | 113.22 | 58.09 | 17 | 2100 | 145 | 42619073 |
| Skin burning sensation | 97.90 | 58.09 | 29 | 2088 | 7458 | 42611760 |
| Blister | 90.08 | 58.09 | 38 | 2079 | 27452 | 42591766 |
| Application site erosion | 86.45 | 58.09 | 13 | 2104 | 112 | 42619106 |
| Application site burn | 85.43 | 58.09 | 14 | 2103 | 219 | 42618999 |
| Skin discolouration | 82.45 | 58.09 | 33 | 2084 | 20857 | 42598361 |
| Cutaneous T-cell lymphoma | 81.02 | 58.09 | 19 | 2098 | 1979 | 42617239 |
| Application site exfoliation | 80.15 | 58.09 | 13 | 2104 | 190 | 42619028 |
| Second primary malignancy | 78.66 | 58.09 | 26 | 2091 | 9549 | 42609669 |
| Application site swelling | 73.30 | 58.09 | 13 | 2104 | 331 | 42618887 |
| Application site reaction | 70.84 | 58.09 | 13 | 2104 | 403 | 42618815 |
| Disease progression | 65.01 | 58.09 | 55 | 2062 | 143601 | 42475617 |
| Application site scab | 61.25 | 58.09 | 9 | 2108 | 65 | 42619153 |
| Dermatitis | 58.32 | 58.09 | 22 | 2095 | 11853 | 42607365 |
| Application site dryness | 58.28 | 58.09 | 9 | 2108 | 94 | 42619124 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 979.81 | 48.39 | 163 | 3830 | 3997 | 110581309 |
| Application site erythema | 804.41 | 48.39 | 144 | 3849 | 5466 | 110579840 |
| Application site pain | 715.28 | 48.39 | 130 | 3863 | 5369 | 110579937 |
| Application site irritation | 421.22 | 48.39 | 71 | 3922 | 1866 | 110583440 |
| Application site discolouration | 338.58 | 48.39 | 54 | 3939 | 995 | 110584311 |
| Pruritus | 322.89 | 48.39 | 220 | 3773 | 581340 | 110003966 |
| Skin irritation | 309.34 | 48.39 | 79 | 3914 | 16240 | 110569066 |
| Application site vesicles | 282.89 | 48.39 | 49 | 3944 | 1515 | 110583791 |
| Skin discolouration | 231.22 | 48.39 | 81 | 3912 | 48965 | 110536341 |
| Erythema | 224.56 | 48.39 | 136 | 3857 | 291311 | 110293995 |
| Therapy non-responder | 205.28 | 48.39 | 104 | 3889 | 157203 | 110428103 |
| Application site discharge | 192.25 | 48.39 | 29 | 3964 | 363 | 110584943 |
| Skin burning sensation | 179.66 | 48.39 | 55 | 3938 | 21770 | 110563536 |
| Application site dryness | 162.62 | 48.39 | 24 | 3969 | 256 | 110585050 |
| Application site exfoliation | 138.52 | 48.39 | 23 | 3970 | 547 | 110584759 |
| Cutaneous T-cell lymphoma | 135.34 | 48.39 | 30 | 3963 | 3354 | 110581952 |
| Application site swelling | 128.36 | 48.39 | 23 | 3970 | 864 | 110584442 |
| Disease progression | 114.93 | 48.39 | 84 | 3909 | 243950 | 110341356 |
| Application site erosion | 112.86 | 48.39 | 18 | 3975 | 330 | 110584976 |
| Application site reaction | 109.74 | 48.39 | 20 | 3973 | 827 | 110584479 |
| Application site inflammation | 107.77 | 48.39 | 18 | 3975 | 444 | 110584862 |
| Skin hyperpigmentation | 102.66 | 48.39 | 29 | 3964 | 8667 | 110576639 |
| Application site burn | 99.81 | 48.39 | 19 | 3974 | 998 | 110584308 |
| Dermatitis | 97.58 | 48.39 | 37 | 3956 | 27800 | 110557506 |
| Application site rash | 94.01 | 48.39 | 21 | 3972 | 2429 | 110582877 |
| Application site scab | 90.05 | 48.39 | 14 | 3979 | 216 | 110585090 |
| Dry skin | 84.45 | 48.39 | 51 | 3942 | 107602 | 110477704 |
| Blister | 73.97 | 48.39 | 63 | 3930 | 227313 | 110357993 |
| Cutaneous T-cell lymphoma recurrent | 68.89 | 48.39 | 10 | 3983 | 94 | 110585212 |
| Skin exfoliation | 67.37 | 48.39 | 41 | 3952 | 87610 | 110497696 |
| Second primary malignancy | 63.25 | 48.39 | 24 | 3969 | 18044 | 110567262 |
| Scab | 58.97 | 48.39 | 21 | 3972 | 13215 | 110572091 |
| Application site haemorrhage | 58.36 | 48.39 | 13 | 3980 | 1483 | 110583823 |
| Lymphomatoid papulosis | 55.06 | 48.39 | 10 | 3983 | 405 | 110584901 |
| Dermatitis contact | 50.52 | 48.39 | 19 | 3974 | 13934 | 110571372 |
| Skin lesion | 49.81 | 48.39 | 28 | 3965 | 51603 | 110533703 |
| Skin disorder | 48.95 | 48.39 | 26 | 3967 | 42887 | 110542419 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01AA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
| FDA MoA | N0000000236 | Alkylating Activity |
| FDA EPC | N0000175558 | Alkylating Drug |
| MeSH PA | D000477 | Alkylating Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D002619 | Chemical Warfare Agents |
| MeSH PA | D007509 | Irritants |
| MeSH PA | D011042 | Poisons |
| MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
| CHEBI has role | CHEBI:22333 | alkylating agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01AA Nitrogen mustard analogues 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic lymphoid leukemia, disease | indication | 92814006 | |
| Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
| Polycythemia vera | indication | 109992005 | |
| Hodgkin's disease | indication | 118599009 | |
| Non-Hodgkin's lymphoma | indication | 118601006 | |
| Mycosis fungoides | indication | 118618005 | |
| Malignant tumor of lung | indication | 363358000 | |
| Primary cutaneous T-cell lymphoma | indication | 400122007 | |
| Pericardial Malignant Effusions | indication | ||
| Peritoneal Malignant Effusions | indication | ||
| Pleural Malignant Effusions | indication | ||
| Amyloidosis | contraindication | 17602002 | DOID:9120 |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Acute infectious disease | contraindication | 63171007 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Secondary malignant neoplasm of bone marrow | contraindication | 94217008 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Chemotherapy-Induced Hyperuricemia | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.7 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 8501819 | March 7, 2026 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 7872050 | July 8, 2029 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4019808 | VUID |
| N0000147897 | NUI |
| D04872 | KEGG_DRUG |
| 55-86-7 | SECONDARY_CAS_RN |
| 4017994 | VANDF |
| 4019808 | VANDF |
| C0025033 | UMLSCUI |
| CHEBI:28925 | CHEBI |
| CHEMBL427 | ChEMBL_ID |
| DB00888 | DRUGBANK_ID |
| CHEMBL1201001 | ChEMBL_ID |
| D008466 | MESH_DESCRIPTOR_UI |
| 4033 | PUBCHEM_CID |
| 586 | INN_ID |
| 7218 | IUPHAR_LIGAND_ID |
| 50D9XSG0VR | UNII |
| 155036 | RXNORM |
| 1972 | MMSL |
| 29634 | MMSL |
| 5028 | MMSL |
| d01339 | MMSL |
| 002630 | NDDF |
| 004816 | NDDF |
| 29156002 | SNOMEDCT_US |
| 372692002 | SNOMEDCT_US |
| 387071000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |